Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...

WASHINGTON, Jan 15 - A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' (NOVN.S), opens new tab blockbuster heart-failure drug ...

with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillationAcquisition adds a late-stage asset and is aligned with Novartis strategic focus ...

A federal appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic version of its blockbuster heart failure drug Entresto. The US Court of Appeals ...

WASHINGTON -A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' blockbuster heart-failure drug Entresto late on Wednesday.

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth. After signing 30 deals ...

Entresto’s importance to Novartis is illustrated in the company’s most recent quarterly report, which revealed that the drug generated $5.6 billion in the first three quarters of 2024 ...

Rose Hill is an 85 acre green and gothic campus and is home to Fordham College at Rose Hill, the Gabelli School of Business, the School of Professional and Continuing Studies as well as the Graduate ...

WASHINGTON, Jan 16 - Novartis (NOVN.S), opens new tab won an order from a U.S. appeals court in Washington on Thursday temporarily blocking drugmaker MSN Pharmaceuticals from launching a generic ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.